
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7496761/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology, 2022, 61, 1376-1384.	1.9	26
2	DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses. Biometrical Journal, 2022, 64, 1486-1497.	1.0	1
3	Anti–Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema. Ophthalmology, 2022, 129, 520-529.	5.2	32
4	Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. American Journal of Gastroenterology, 2022, 117, 627-636.	0.4	9
5	Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. American Journal of Ophthalmology, 2022, 238, 173-180.	3.3	13
6	Cerebrovascular Ischemic Events in Patients With Takayasu Arteritis. Stroke, 2022, 53, 1550-1557.	2.0	12
7	Association of COVID-19 Acute Respiratory Distress Syndrome With Symptoms of Posttraumatic Stress Disorder in Family Members After ICU Discharge. JAMA - Journal of the American Medical Association, 2022, 327, 1042.	7.4	49
8	PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2022, 23, 491-500.	10.7	20
9	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome―by Quartuccio et al. Joint Bone Spine. 2020;87:191–93. Joint Bone Spine, 2021, 88, 105074.	1.6	5
10	A simulation study of approaches for handling disease progression in dose-finding clinical trials. Journal of Biopharmaceutical Statistics, 2021, 31, 156-167.	0.8	8
11	Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1191-1198.	2.9	7
12	Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trials. Contemporary Clinical Trials Communications, 2021, 21, 100709.	1.1	5
13	Direct oral anticoagulant for venous thrombosis in Behçet's syndrome. Autoimmunity Reviews, 2021, 20, 102783.	5.8	7
14	Seamless phase I/II design for novel anticancer agents with competing disease progression. Statistics in Medicine, 2021, 40, 4568-4581.	1.6	5
15	Spectrum and Outcome of Noninfectious Aortitis. Journal of Rheumatology, 2021, 48, 1583-1588.	2.0	4
16	Non–C. difficileClostridioides Bacteremia in Intensive Care Patients, France. Emerging Infectious Diseases, 2021, 27, 1840-1849.	4.3	5
17	Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome. Journal of Rheumatology, 2020, 47, 896-902.	2.0	21
18	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. PLoS ONE, 2020, 15, e0240711.	2.5	54

#	Article	IF	CITATIONS
19	Dose-finding design and benchmark for a right censored endpoint. Journal of Biopharmaceutical Statistics, 2020, 30, 948-963.	0.8	6
20	Outcomes in 886 Critically Ill Patients After Near-Hanging Injury. Chest, 2020, 158, 2404-2413.	0.8	10
21	Cardiac sarcoidosis: A long term follow up study. PLoS ONE, 2020, 15, e0238391.	2.5	32
22	Correspondance on â€~Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases'. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219566.	0.9	0
23	Neutrophil–Platelet and Monocyte–Platelet Aggregates in COVID-19 Patients. Thrombosis and Haemostasis, 2020, 120, 1733-1735.	3.4	41
24	Cryoglobulinemia after the era of chronic hepatitis C infection. Seminars in Arthritis and Rheumatism, 2020, 50, 695-700.	3.4	23
25	Long-Term Outcome and Prognosis Factors of Isolated Aortitis. Circulation, 2020, 142, 92-94.	1.6	22
26	Infectious disease consultation for candidaemia. Lancet Infectious Diseases, The, 2020, 20, 164-165.	9.1	2
27	Title is missing!. , 2020, 15, e0240711.		0
28	Title is missing!. , 2020, 15, e0240711.		0
29	Title is missing!. , 2020, 15, e0240711.		0
30	Title is missing!. , 2020, 15, e0240711.		0
31	Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. Journal of Autoimmunity, 2019, 96, 35-39.	6.5	61
32	Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. Frontiers in Immunology, 2019, 10, 1665.	4.8	31
33	TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. Journal of Hepatology, 2019, 71, 908-919.	3.7	23
34	Long-term health-related quality of life of critically ill patients with haematological malignancies: a prospective observational multicenter study. Annals of Intensive Care, 2019, 9, 2.	4.6	17
35	Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. Leukemia and Lymphoma, 2019, 60, 2802-2805.	1.3	10
36	Center Effects in Hospital Mortality of Critically III Patients With Hematologic Malignancies*. Critical Care Medicine, 2019, 47, 809-816.	0.9	12

#	Article	IF	CITATIONS
37	Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. Annals of Hematology, 2019, 98, 195-203.	1.8	5
38	Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. International Journal of Infectious Diseases, 2019, 79, 179-184.	3.3	36
39	Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies. Leukemia and Lymphoma, 2019, 60, 1156-1163.	1.3	6
40	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1 <sup>+</sup> Tim-3 <sup>+</sup> CD8 <sup>+</sup> T Cells. Journal of Visualized Experiments, 2018, , .	0.3	14
41	Acute kidney injury in critically ill patients with solid tumours. Nephrology Dialysis Transplantation, 2018, 33, 1997-2005.	0.7	26
42	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Oncolmmunology, 2017, 6, e1286437.	4.6	28
43	Gastrointestinal emergencies in critically ill cancer patients. Journal of Critical Care, 2017, 40, 69-75.	2.2	14
44	Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. JAMA Neurology, 2017, 74, 1336.	9.0	76
45	Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. Circulation, 2017, 136, 1114-1122.	1.6	161
46	Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. Cancer Research, 2017, 77, 1075-1082.	0.9	166
47	Severe infections in sarcoidosis. Medicine (United States), 2017, 96, e8846.	1.0	46
48	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis and Rheumatology, 2016, 68, 1522-1530.	5.6	131
49	<sup>18</sup> F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. Journal of Nuclear Medicine, 2016, 57, 536-543.	5.0	40
50	Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT. Blood, 2016, 128, 3488-3488.	1.4	0
51	Impact of the source of hematopoietic stem cell in unrelated transplants: Comparison between 10/10, 9/10â€∢scp>HLA matched donors and cord blood. American Journal of Hematology, 2015, 90, 897-903.	4.1	14
52	Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. European Journal of Dermatology, 2015, 25, 36-44.	0.6	35
53	Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. Clinical and Experimental Rheumatology, 2015, 33, 509-15.	0.8	18
54	Behcet's disease in budd-chiari syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 104.	2.7	57

#	Article	IF	CITATIONS
55	Single-center experience in French Temporary Authorization for Use (TAU) metastatic melanoma program with ipilimumab Journal of Clinical Oncology, 2014, 32, e20034-e20034.	1.6	1
56	Neutropenic Enterocolitis: Clinical Features and Outcomes. Blood, 2014, 124, 5984-5984.	1.4	0
57	Personal Decision-Making Criteria Related to Seasonal and Pandemic A(H1N1) Influenza-Vaccination Acceptance among French Healthcare Workers. PLoS ONE, 2012, 7, e38646.	2.5	17
58	Case-Only Designs in Pharmacoepidemiology: A Systematic Review. PLoS ONE, 2012, 7, e49444.	2.5	32